Allergan to acquire Kythera Biopharmaceuticals in $2.1 billion deal

Allergan announced it has entered into a definitive agreement with Kythera Biopharmaceuticals in a transaction valued at approximately $2.1 billion, according to a press release.Kythera Biopharmaceuticals developed Kybella (deoxycholic acid), otherwise known as ATX-101, which was approved by the FDA on April 29 for the treatment of moderate-to-severe submental fat, or “double chin” in adults. Allergan’s aesthetic portfolio includes Botox (onabotulinumtoxin A) and Juvederm (hyaluronic acid).